Evidence map›Paper›PMID 29499152›Full record

ReviewCell stem cell2018

Vascular Tissue Engineering: Progress, Challenges, and Clinical Promise.

H-H Greco Song, Rowza T Rumma, C Keith Ozaki, Elazer R Edelman, Christopher S Chen

Erratum issuedOpen access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cell stem cell, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 207 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
207citing papers in PubMed, 2 pooled it
19.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

207 citing papers in PubMed, 2 syntheses or guidelines pooled it, 459 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article

147 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

H-H Greco SongHarvard-MIT Program in Health Sciences and Technology, Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Biological Design Center, Department of Biomedical Engineering, Boston University, Boston, MA 02215, USA; Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA 02115, USA.
Rowza T RummaHarvard-MIT Program in Health Sciences and Technology, Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
C Keith OzakiDepartment of Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
Elazer R EdelmanHarvard-MIT Program in Health Sciences and Technology, Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Division of Cardiology, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
Christopher S ChenBiological Design Center, Department of Biomedical Engineering, Boston University, Boston, MA 02215, USA; Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA 02115, USA. Electronic address: chencs@bu.edu.
Brigham and Women's Hospital · USMassachusetts Institute of Technology · USBoston University · US

Funding

REGULATION OF ANGIOGENESIS BY MICROENVIRONMENTAL CUESR01EB000262 · NIBIB · UNIVERSITY OF PENNSYLVANIA · PI CHEN, CHRISTOPHER S · 2002 to 2023
$6.2M
Engineering Multicellular Tissue Structure, Function, and VascularizationR01EB008396 · NIBIB · UNIVERSITY OF PENNSYLVANIA · PI BHATIA, SANGEETA N., CHEN, CHRISTOPHER S · 2009 to 2018
$5.8M
NIBIB NIH HHS R01 EB000262NIBIB NIH HHS R01 EB008396
6 · The paper itself

Abstract

Although the clinical demand for bioengineered blood vessels continues to rise, current options for vascular conduits remain limited. The synergistic combination of emerging advances in tissue fabrication and stem cell engineering promises new strategies for engineering autologous blood vessels that recapitulate not only the mechanical properties of native vessels but also their biological function. Here we explore recent bioengineering advances in creating functional blood macro and microvessels, particularly featuring stem cells as a seed source. We also highlight progress in integrating engineered vascular tissues with the host after implantation as well as the exciting pre-clinical and clinical applications of this technology.

Indexed as

Biocompatible MaterialsBlood VesselsHumansPrinting, Three-DimensionalProstheses and ImplantsStem CellsTissue EngineeringBiocompatible Materials

Identifiers

PMID29499152
PMCPMC5849079
OpenAlexW2791878273

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.